NCT03536325View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

October 25, 2018

Study Completion Date

October 25, 2018

Conditions
Healthy
Interventions
DRUG

Guselkumab Dose 1

Participants will receive Dose 1 of guselkumab on Day 1.

DRUG

Guselkumab Dose 2

Participants will receive Dose 2 of guselkumab on Day 1.

DRUG

Guselkumab Dose 3

Participants will receive Dose 3 of guselkumab on Day 1.

DRUG

Placebo

Participants will receive matching placebo on Day 1.

Trial Locations (1)

812-0025

Souseikai Hakata Clinic, Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY